source
- Caribou Biosciences halts CAR-T programs and cuts staff amid funding shortfallCaribou Biosciences, a CRISPR gene-editing company co-founded by Nobel laureate Jennifer Doudna, announced it will stop work on its off-the-shelf CAR-T cancer therapies. The decision follows the c…
- ArriVent BioPharma's Phase 3 lung cancer trial misses primary endpoint, shares tumbleArriVent BioPharma reported that its investigational EGFR tyrosine kinase inhibitor firmonertinib did not achieve a statistically significant improvement in progression-free survival in the Phase 3…